Oscar Health (OSCR) reported Thursday a Q3 loss of $0.22 per diluted share, narrowing from a loss of $0.29 a year earlier.
Analysts polled by Capital IQ expected a GAAP loss of $0.20.
Revenue for the quarter ended Sept. 30 was $2.42 billion, up from $1.44 billion a year earlier.
Analysts surveyed by Capital IQ expected $2.35 billion.
The company said it expects 2024 revenue of $9.2 billion to $9.3 billion, compared with the previous forecast of $9 billion to $9.1 billion. Analysts polled by Capital IQ expect $9.05 billion.
Price: 16.85, Change: -0.19, Percent Change: -1.12
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。